These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

793 related items for PubMed ID: 29049007

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, Tabrizi SN, VACCINE study group.
    Vaccine; 2018 May 31; 36(23):3221-3230. PubMed ID: 29724506
    [Abstract] [Full Text] [Related]

  • 3. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH, Medical Microbiological Laboratories, Public Health Services.
    J Infect; 2017 Apr 31; 74(4):393-400. PubMed ID: 28126492
    [Abstract] [Full Text] [Related]

  • 4. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, Serradell L, Burroni E, Confortini M, Mantellini P, Zappa M, Dominiak-Felden G.
    BMC Infect Dis; 2018 Jan 15; 18(1):38. PubMed ID: 29334901
    [Abstract] [Full Text] [Related]

  • 5. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 6. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
    Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE.
    J Infect Dis; 2018 Apr 23; 217(10):1579-1589. PubMed ID: 29409034
    [Abstract] [Full Text] [Related]

  • 7. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, Wrede CD, Jayasinghe Y, Gertig DM, Pitts MK, Garland SM, VACCINE Study group.
    Vaccine; 2015 Jan 01; 33(1):201-8. PubMed ID: 25444787
    [Abstract] [Full Text] [Related]

  • 8. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
    Kumakech E, Berggren V, Wabinga H, Lillsunde-Larsson G, Helenius G, Kaliff M, Karlsson M, Kirimunda S, Musubika C, Andersson S.
    PLoS One; 2016 Jan 01; 11(8):e0160099. PubMed ID: 27482705
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
    Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Regan DG, Hocking JS, Garland SM, Cornall AM, Atchison S, Bradshaw CS, McNulty A, Owen L, Marshall L, Russell DB, Kaldor JM, Chen MY.
    Vaccine; 2019 Oct 31; 37(46):6907-6914. PubMed ID: 31562001
    [Abstract] [Full Text] [Related]

  • 10. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
    Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG.
    Br J Cancer; 2016 May 24; 114(11):1261-4. PubMed ID: 27115467
    [Abstract] [Full Text] [Related]

  • 11. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
    Gray P, Luostarinen T, Vänskä S, Eriksson T, Lagheden C, Man I, Palmroth J, Pimenoff VN, Söderlund-Strand A, Dillner J, Lehtinen M.
    Int J Cancer; 2019 Aug 01; 145(3):785-796. PubMed ID: 30719706
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of Vaccine Type Infections in Vaccinated and Non-Vaccinated Young Women: HPV-IMPACT, a Self-Sampling Study.
    Jeannot E, Viviano M, de Pree C, Amadane M, Kabengele E, Vassilakos P, Petignat P.
    Int J Environ Res Public Health; 2018 Jul 09; 15(7):. PubMed ID: 29987255
    [Abstract] [Full Text] [Related]

  • 13. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
    Loenenbach A, Schönfeld V, Takla A, Wiese-Posselt M, Marquis A, Thies S, Sand M, Kaufmann AM, Wichmann O, Harder T.
    Front Public Health; 2023 Jul 09; 11():1204101. PubMed ID: 37719724
    [Abstract] [Full Text] [Related]

  • 14. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
    Enerly E, Flingtorp R, Christiansen IK, Campbell S, Hansen M, Myklebust TÅ, Weiderpass E, Nygård M.
    PLoS One; 2019 Jul 09; 14(10):e0223612. PubMed ID: 31600341
    [Abstract] [Full Text] [Related]

  • 15. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
    Combita AL, Reyes V, Puerto D, Murillo R, Sánchez R, Nuñez M, Hernandez-Suarez GA, Wiesner C.
    Cancer Prev Res (Phila); 2022 Jan 09; 15(1):55-66. PubMed ID: 34610993
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.
    Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA.
    Wien Klin Wochenschr; 2008 Jan 09; 120(21-22):666-71. PubMed ID: 19116707
    [Abstract] [Full Text] [Related]

  • 17. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun 09; 16(89):91-4. PubMed ID: 17582921
    [Abstract] [Full Text] [Related]

  • 18. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.
    Ji J, Sun HK, Smith JS, Wang H, Esser MT, Hu S, Pretorius RG, Chen W, Belinson JL, Qiao YL.
    BMC Infect Dis; 2012 Jun 20; 12():137. PubMed ID: 22715915
    [Abstract] [Full Text] [Related]

  • 19. Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine.
    Bretagne CH, Jooste V, Guenat D, Riethmuller D, Bouvier AM, Bedgedjian I, Prétet JL, Valmary-Degano S, Mougin C.
    J Gynecol Obstet Hum Reprod; 2018 Dec 20; 47(10):525-531. PubMed ID: 29807205
    [Abstract] [Full Text] [Related]

  • 20. [Value of general human papillomavirus vaccination in sexually active women].
    Hampl M.
    Dtsch Med Wochenschr; 2009 Apr 20; 134 Suppl 2():S95-9. PubMed ID: 19353480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.